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Hypoglycemia is well-recognized to limit the degree of glycemic control possible for many
individuals for diabetes. Although the likelihood of hypoglycemia increases as A1c levels
decrease in type 1 diabetes, insulin-treated type 2 diabetic persons with higherA1c appear
paradoxically to have more hypoglycemia which may explain, in part, the adverse outcome
reported in the ACCORD study. Approaches to glucose-lowering that cause lesser degrees
of risk for hypoglycemia, technologies to better ascertain hypoglycemic events, and better
understanding of patient characteristics associated with greater likelihood of hypoglycemia
will all be required to reduce this limiting factor in optimizing glycemic treatment.
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Attempts to determine whether intensive glycemic treatment
would be associated with reduction in adverse cardiovascular out-
comes led to three large recent randomized controlled trials: the
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
trial, the Action in Diabetes and Vascular Disease: Preterax and
Diamicron MR Controlled Evaluation (ADVANCE) trial, and the
Veteran’s Administration Diabetes Trial (VADT). A widely held,
but inaccurate interpretation has been that none of these studies
suggested beneﬁt from intensive glycemic control. In ADVANCE,
thecombinationof intensiveglycemictreatmentalongwithblood
pressure-lowering with a diuretic and angiotensin-directed ther-
apyreducedmortality(Zoungasetal.,2009),andanepidemiologic
analysis of different levels of on-trial glycemia showed optimal
outcome with normal to near-normal A1c levels (Zoungas et al.,
2012). In ACCORD there was consistent evidence of reduction
in microvascular endpoints,with the intensively treated subgroup
showing 30% reduction in retinopathy, while the likelihood of
non-fatal myocardial infarction was signiﬁcantly reduced by 21%
(Boussageon et al., 2011; Hemmingsen et al., 2011). There was,
however, a signiﬁcant 26% increase in mortality in this study,
which has been a major source of concern.
Over the past few years, there has been increasing recognition
of the importance of hypoglycemia as an adverse consequence
of treatment of type 2 diabetes. Previously, severe hypoglycemia
was thought to be relatively rare in type 2 diabetes and perhaps
not as important as in type 1 diabetes. The ACCORD, VADT,
and ADVANCE trials have, however, underscored the concern
withhypoglycemia-relatedadverseoutcomes.Furthermore,hypo-
glycemia in type 2 diabetes is associated with longer length of
hospital stay, greater cost, and higher mortality during hospi-
talization (Curkendall et al., 2009; Turchin et al., 2009). Impor-
tant observations have shown greater risk of speciﬁc types of
hypoglycemia. Spontaneous hypoglycemia following myocardial
infarction is associated with increased mortality, while insulin-
inducedhypoglycemiaaftermyocardialinfarctionwasnot,leading
to the conclusion that persons experiencing hypoglycemia might
be particularly at risk of adverse outcome not directly related
to glucose effects, but rather because of concomitant underlying
characteristics such as greater degrees of renal insufﬁciency (Kosi-
borod et al., 2009). Based on these observations, it has become
apparent that it is important to include the implications of hypo-
glycemia in realistic goal-setting for treatment approaches in type
2 diabetes.
It had been thought for some time that with improvement
in glycemic control, i.e., overall lowering of average glucose, the
likelihood of hypoglycemia would increase. The concept seemed
logical, and was indeed conﬁrmed among type 1 diabetics in the
Diabetes Control and Complications Trial where annual severe
hypoglycemia frequency increased from ∼30 to 90 incidents per
100 person-years as mean A1c decreased from 9 to 6% (The Dia-
betes Control and Complications Trial Research Group, 1993). It
should be noted that this trial preceded the newer and more pre-
dictable analog insulin preparations, and the widespread use of
self monitoring of blood glucose levels.
In type 2 diabetes, however, the situation is more complex.
Among diet, sulfonylurea (SU), or metformin-treated type 2 dia-
betic patients in the United Kingdom Prospective Diabetes Study
(UKPDS), total annual hypoglycemia rates increased from ∼2
to 6% as the most recent on-trial A1c level decreased from 9
to 6%. Paradoxically, however, for insulin-treated patients in the
study, almost all of whom were receiving just one daily long-
acting insulin dose, the respective hypoglycemia rates actually
decreased from ∼25 to 18% (Wright et al., 2006). Those persons
who,despitetheuseof insulin,didnotachievegoodglycemiccon-
trol were, then, particularly at risk of hypoglycemia (Figure 1A).
The implication appears to be that insulin treatment in type
2 diabetes alters the equation, perhaps because, as observed in
other trials, patients with better control actually have less hypo-
glycemia. This may relate to lesser degrees of insulin secretory
deﬁciency, or to factors such as adherence, which are crucial
in the successful outcome of any efforts to improve glycemic
control.
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FIGURE1|( A )total (grades 1–4) and severe (grades 2–4) hypoglycemia in UKPDS (Hemmingsen et al., 2011). (B) Hypoglycemia vs. on-trial A1c in the intensive
(blue) and conventional treatment (dotted red) groups of ACCORD (Kendall et al., 2005).
These concepts are highly important in understanding the
adverse outcome reported in theACCORD study. The group with
the worst outcome was the subset of the tight control group that
could not, for whatever reason, achieve tight control (Figure 1B).
An attractive hypothesis is that targeting near-normal levels of
glucose may not be the problem, but rather that harm results
from the treatments unsuccessfully employed to accomplish this
in individuals who are nevertheless unable to improve glycemia.
While we do not know what factors led to the failure of individ-
uals to achieve best control, it seems reasonable to suspect that
they had a higher rate of undocumented hypoglycemia which
may have been responsible, at least in part, for their adverse
outcome.
In UKPDS total hypoglycemia rates were more than 10-fold
greater than rates of severe hypoglycemia, and insulin-treated
patients had rates approximately three-fold greater than that of
diet- and metformin-treated persons, while SU were associated
with intermediate hypoglycemia rates [UK Prospective Diabetes
Study , UKPDS]. UKPDS was, it should be noted, conducted
with older insulin preparations, which are less predictable, caus-
ing hypoglycemia with greater frequency than seen with newer
analogs. The pattern of highest hypoglycemia rates with insulin
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and intermediate increase in hypoglycemia with SU has been
reported in many studies of type 2 diabetes (Nissen et al., 2008),
with further data suggesting that the SU are particularly likely to
causehypoglycemiaduringtheﬁrstfewmonthsof theiruse(Bod-
mer et al., 2008), the period of their greatest glucose-lowering
potency (Kahn et al., 2006). Increased hypoglycemia likelihood
also is seen with SU in combination with metformin, with thi-
azolidinediones, and with incretin-based treatments (Buse et al.,
2004; Kendall et al., 2005; Bolen et al., 2007; Nauck et al., 2007;
Arechavaleta et al., 2011). In contrast, incretin-based treatments
when given without a SU are noteworthy for the rarity of hypo-
glycemia,evenwithsubstantialglucose-lowering(Neumilleretal.,
2010; MacConell et al.,2012).
Hypoglycemia is an important consideration in the choice
of approaches to insulin treatment. Studies comparing insulin
glargine with neutral protamine Hagedorn insulin show a reduc-
tion in total and severe hypoglycemia by ∼25% with the former
(Riddle et al., 2003). The use of basal insulin detemir as pri-
marytreatmentleadstotwoandthreefoldloweroveralllikelihood
of hypoglycemia than multiple dose biphasic or prandial insulin
(Holman et al., 2007, 2009). An even greater reduction of hypo-
glycemia was reported in a comparison of insulin glargine with
insulin lispro three times daily (Bretzel et al.,2008).
Treatment associated with hypoglycemia may have substantial
adverse clinical consequences. In the BARI 2D trial of therapies
for type 2 diabetes in patients with coronary artery disease, treat-
ment approaches based on use of SU and/or insulin were ∼50%
more likely both to cause total and severe hypoglycemia than were
insulin sensitization with metformin and rosiglitazone, with a
suggestion of worse CV outcome (BARI 2D Study Group et al.,
2009). One must wonder whether hypoglycemia, not only in the
severe symptomatic form, but also in the much more common
forms with minor symptoms or even altogether lacking symp-
toms, may have consequences in persons with coronary disease,
cardiac arrhythmia, or diabetic autonomic neuropathy, because
of increasing vasoactive cytokine release with consequent increase
in myocardial ischemia. Certainly a number of arguments can be
put forward to suggest that hypoglycemia may be pro-arrhythmic
(Nordin, 2010) and/or that it may contribute to unstable ath-
erosclerotic plaque and events weeks to months after the actual
hypoglycemia.
In ACCORD, annual hypoglycemia rates were 3.3 vs. 1.1% in
theintensivevs.standardcontrolgroup(Milleretal.,2010).About
9,546 participants did not have documented severe hypoglycemia,
and those randomized to intensive treatment had a 1.24-fold
greater annual mortality than those in the standard treatment
group. However, 705 participants had one or more episode of
severe hypoglycemia, with annual mortality approximately 3-fold
that in those not experiencing hypoglycemia. In the group with
hypoglycemia, paradoxically, the mortality risk was ∼60% lower
amongthoseassignedtointensiveglycemictreatment(Figure2A).
Severe hypoglycemia was more common with longer duration of
diabetes, with lower body weight, with greater degrees of renal
disease(bothintermsof albuminuriaandserumcreatinine),with
peripheralneuropathy,inAfrican-Americans,andinfemales.Sim-
ilarly, in ACCORD, in both the intensive and standard treatment
groups the severe hypoglycemia rates were more frequent in those
FIGURE2|( A )Association of severe hypoglycemia with mortality in
intensive and standard treatment groups in ACCORD replotted from Bonds
et al. (2010). (B) Association of severe hypoglycemia with mortality in
intensive and standard treatment groups in ADVANCE replotted from
Holman et al. (2009).
with higher,rather than lower,levels of A1c (Figure1B). Further-
more, those in the intensive treatment group who failed to show
at least a 0.5% reduction in A1c during the ﬁrst year of the study
had higher mortality,with higher mean on-trialA1c in this group
associatedwithgreaterlikelihoodofmortality(Riddleetal.,2010).
Two thirds of deaths were in the “unexpected/sudden” category
(Action to Control Cardiovascular Risk in Diabetes Study Group
et al., 2008), consistent with the association with hypoglycemia.
In keeping with the supposition that those having greater difﬁ-
culty attaining glycemic control might be at a particular risk due
to intensive treatment, analysis showed no increase in mortality
among those in the intensive treatment group with baseline A1c
<7.5%, or 7.5–8.5%, while mortality was 1.7-fold increased in
those in the intensive treatment group with baseline A1c >8.5%
(Calles-Escandón et al., 2010). In other words, it bears repeated
emphasis that it was the failure to achieve tight control despite
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best efforts that was the reason for excess mortality in the most
intensivelytreatedgroupinACCORD.ThosewithlowerA1clevels
did better than those with higher A1c.
The ADVANCE trial showed a remarkably similar relation-
ship to that inACCORD between severe hypoglycemia,treatment
assigned,andmortalityrisk(Figure2B).Severehypoglycemiarisk
factors, as in ACCORD, were longer duration of diabetes, lower
body weight, greater degrees of renal disease (both higher serum
creatinine and albuminuria),and cigarette smoking. Interestingly,
in ADVANCE there were associations of severe hypoglycemia
with total and CV mortality, as well as with microvascular and
macrovascular events, and respiratory, skin, and digestive tract
illnesses. These associations have led some to hypothesize that
hypoglycemia may be a marker of propensity to develop illness,
rather than itself being causally related to the various compli-
cations (Zoungas et al., 2010). Macrovascular events and CV
mortality not only occurred around the time of episodes of severe
hypoglycemia, but continued to occur with increased frequency
for 2years after the index hypoglycemic event, supporting the
hypothesis that hypoglycemia may be a marker of poor prog-
nosis, rather than its cause. Interestingly, minor hypoglycemia
had entirely different associations in the trial, being associated
with lower rates of macrovascular disease and of total and car-
diovascularmortality.IntheVADTtoo,severehypoglycemiarates
werethreefoldgreaterwithintensivetreatment,andhypoglycemia
increased mortality risk, with sudden death again appearing to
accountfortheexcessinmortalityintheintensivetreatmentgroup
(Bloomgarden, 2008).
The ACCORD investigators report, however, that severe hypo-
glycemia did not appear to explain the increase in mortality seen
in the intensively treated group. It is difﬁcult to fully support
this viewpoint, as severe hypoglycemia certainly was associated
with increased mortality in this and in the other trials, and as
the glycemic intervention was itself associated with an increase
in the likelihood of severe hypoglycemia. The lack of associa-
tion of severe hypoglycemia with mortality may reﬂect incom-
plete ascertainment of events, as the investigators only tracked
severe symptomatic hypoglycemia, while, in fact, episodes with
minor symptoms or lacking symptoms occur more frequently
thansymptomaticones(Swinnenetal.,2009).Clearly,fullanalysis
of self-monitored blood glucose measurements performed by the
participantsinACCORDwouldbelikelytogivemuchmoreinfor-
mation about hypoglycemia risk in this population (Kovatchev
etal.,2000),whichwouldclarifywhetherthereisindeedarelation-
ship between hypoglycemia and adverse outcome. The alternative
hypothesis discussed above is that hypoglycemia may be seen as
a marker of greater “illness,” in association with multiple adverse
outcomes,some of which may not be directly related to the blood
sugar, so that more frail patients may be at risk both for hypo-
glycemia and for mortality. Behavioral and psychological factors
associated with being unable to adhere to a diabetes regimen have
also been hypothesized.
The risk of hypoglycemia per se should perhaps not be used
as a rationale to not attempt best possible, safe glycemic con-
trol.BetterA1cstillprovidesbetteroutcomes,recognizingthatthe
degreeofglucose-loweringmustbeindividualizedbasedonmulti-
ple different characteristics of individual patients (Blonde, 2012).
Agents that can reduce A1c without hypoglycemia risk, such as
the incretins and the TZDs,may deserve prominence in the treat-
ment algorithm, and we look forward to studies designed to test
the hypothesis of whether this is in fact the case. Glycemic vari-
ability may be another factor explaining adverse outcome (Hirsch
and Brownlee, 2005), although the argument for this as a factor
independent of hypoglycemia is by no means deﬁnite (Kilpatrick,
2009). We may, then, paraphrase Joslin’s remark, made shortly
after the introduction of insulin,to state,“intensive diabetes man-
agement is a remedy primarily for the wise and not for the foolish,
whether they be patients or doctors.”(Joslin, 1928).
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